Literature DB >> 20414166

On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome.

Salvatore Gentile1.   

Abstract

INTRODUCTION: Late in utero exposure to antidepressants has been suspected of adversely impacting pregnancy outcome and compromising neonatal adaptation. Hence, the necessity exists to analyze published information on antidepressant use during late pregnancy to individuate potential recurrent patterns of iatrogenic complications.
METHODS: Computerized searches on MEDLINE, PsycINFO, ENBASE, and Cochrane Library through February 10, 2010 were performed for selecting literature information and investigating the safety of antidepressants when used during late pregnancy.
RESULTS: Antidepressant treatment during late pregnancy may increase the rates of poor pregnancy outcome and neonatal withdrawal/toxic reactions.
CONCLUSIONS: Because both gestational complications and neonatal adverse events acknowledge the same etiology, the author suggests including such iatrogenic events under the definition of prenatal antidepressant exposure syndrome, in order to increase clinicians' awareness about the spectrum of risks which may concern the mother-infant pair when antidepressant treatment is deemed indispensable during late pregnancy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20414166     DOI: 10.1017/s1092852900027449

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  14 in total

Review 1.  Central nervous system effects of prenatal selective serotonin reuptake inhibitors: sensing the signal through the noise.

Authors:  Tamar L Gur; Deborah R Kim; C Neill Epperson
Journal:  Psychopharmacology (Berl)       Date:  2013-05-17       Impact factor: 4.530

2.  Neonatal adaptation following intrauterine antidepressant exposure: assessment, drug assay levels, and infant development outcomes.

Authors:  Megan Galbally; Olav Spigset; Andrew R Johnson; Rolland Kohan; Martha Lappas; Andrew J Lewis
Journal:  Pediatr Res       Date:  2017-08-16       Impact factor: 3.756

Review 3.  Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

Authors:  Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Ther       Date:  2011-04-05       Impact factor: 12.310

4.  Antenatal Escitalopram Use and Necrotizing Enterocolitis in a Newborn: A Case Report.

Authors:  Nilima Jawale; Alok Bhutada; Shantanu Rastogi
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Nov-Dec

5.  Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors.

Authors:  Megan V Smith; Anita Sung; Bhavesh Shah; Linda Mayes; Deborah S Klein; Kimberly A Yonkers
Journal:  Early Hum Dev       Date:  2012-09-20       Impact factor: 2.079

6.  Pharmacological management of borderline personality disorder in a pregnant woman with a previous history of alcohol addiction: a case report.

Authors:  Salvatore Gentile
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

7.  Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine.

Authors:  Cesario Bellantuono; Alessandra Marini; Chiara Lucarelli
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

8.  Early morbidity and mortality following in utero exposure to selective serotonin reuptake inhibitors: a population-based study in Western Australia.

Authors:  Lyn Colvin; Linda Slack-Smith; Fiona J Stanley; Carol Bower
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 9.  Suicidal mothers.

Authors:  Salvatore Gentile
Journal:  J Inj Violence Res       Date:  2011-07

10.  Early neurological outcome of young infants exposed to selective serotonin reuptake inhibitors during pregnancy: results from the observational SMOK study.

Authors:  Nathalie K S de Vries; Christine N van der Veere; Sijmen A Reijneveld; Arend F Bos
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.